Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

Previous
Previous

Bridge Labs Expansion Coming to Pegagus Park in 2024

Next
Next

The Last Word: Dr. Adrian Denvir on Selecting Nine Startups for the HSC Next SBIR Phase 0 Program